Home > Healthcare > Pharmaceuticals > Finished Drug Form > Methicillin-resistant Staphylococcus Aureus Drugs Market

Methicillin-resistant Staphylococcus Aureus Drugs Market Share

Report ID: GMI9303
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Methicillin-resistant Staphylococcus Aureus Drugs Market Share

The methicillin-resistant staphylococcus aureus drugs industry is characterized by the presence of leading pharmaceutical companies. The key market players include Johnson & Johnson, AbbVie Inc., Merck & Co., Inc., and Novartis AG which are focused on developing improved treatments, such as longer-acting formulations and innovative therapies. Market players compete on factors like efficacy, safety, patient convenience, and cost-effectiveness.

Methicillin-resistant Staphylococcus Aureus Drugs Market Companies

Prominent players operating in the methicillin-resistant staphylococcus aureus drugs industry include:

AbbVie Inc.
Basilea Pharmaceutica Ltd
Baxter International Inc.
Cumberland Pharmaceuticals Inc.
GlaxoSmithKline plc.
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global methicillin-resistant staphylococcus aureus (MSRA) drugs market was valued at USD 4.1 billion in 2023 and is anticipated to grow at 4.2% CAGR between 2024

The glycopeptides segment in the MSRA drugs market reached USD 1.2 billion in 2023, owing to their broad-spectrum activity against gram-positive bacteria, including MRSA, and their established efficacy in treating severe MRSA infections.

North America methicillin-resistant staphylococcus aureus drugs market is anticipated to grow at 3.9% CAGR till 2032, attributed to advanced healthcare infrastructure, high awareness levels about infectious diseases, and robust research and development activities.

AbbVie Inc., Basilea Pharmaceutica Ltd, Baxter International Inc., Cumberland Pharmaceuticals Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.